Literature DB >> 11854227

Lymphocyte recruitment and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior Mycobacterium bovis BCG immunization.

Umaimainthan Palendira1, Andrew G D Bean, Carl G Feng, Warwick J Britton.   

Abstract

Mycobacterium tuberculosis infects humans through the lung, and immunity to this chronic infection is mediated primarily by CD4(+) T lymphocytes. Recently we have demonstrated that the recruitment of lymphocytes to the lung during primary aerosol M. tuberculosis infection in mice occurs predominantly through the interaction of alpha(4)beta(1) integrin on CD4(+) T cells and vascular cell adhesion molecule-1 on the pulmonary endothelium. To investigate the effect of route of immunization with Mycobacterium bovis BCG on the pattern of T-cell recruitment to the lung, we have analyzed the differences in expression of integrins on activated memory CD4(+) T cells infiltrating the lung following primary BCG immunization by aerosol, intravenous, and subcutaneous routes and after subsequent aerosol challenge with M. tuberculosis. There were marked differences in the patterns of recruitment of activated CD4(+) T cells to the lung following primary immunization by the three routes. Expansion of CD44(hi) CD62L(low) CD4(+) T cells in the lung occurred following aerosol and intravenous BCG immunizations, and the lymphocyte recruitment was proportional to the pulmonary bacterial load. The majority of infiltrating CD4(+) T cells expressed alpha(4)beta(1) integrin. On subsequent exposure to aerosol BCG rapid expansion of gamma interferon-secreting alpha(4)beta(1)(+) CD4(+) T cells occurred to the same extent in all immunized mice, regardless of the route of immunization. Similar expansion of alpha(4)beta(1)(+) CD4(+) memory T cells occurred following M. tuberculosis challenge. The three routes of BCG immunization resulted in the same level of protection against aerosol M. tuberculosis or BCG challenge in both the lungs and spleen. Therefore, recruitment of effector T lymphocytes and protective efficacy against pulmonary mycobacterial infection are independent of the route of prior BCG immunization.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11854227      PMCID: PMC127792          DOI: 10.1128/IAI.70.3.1410-1416.2002

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  The kinetics of emergence and loss of mediator T lymphocytes acquired in response to infection with Mycobacterium tuberculosis.

Authors:  I M Orme
Journal:  J Immunol       Date:  1987-01-01       Impact factor: 5.422

Review 2.  Modern vaccines. Mycobacterial diseases.

Authors:  P E Fine; L C Rodrigues
Journal:  Lancet       Date:  1990-04-28       Impact factor: 79.321

3.  Cell adhesion molecules on vessels during inflammation in the mouse central nervous system.

Authors:  B Engelhardt; F K Conley; E C Butcher
Journal:  J Neuroimmunol       Date:  1994-05       Impact factor: 3.478

Review 4.  Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm.

Authors:  T A Springer
Journal:  Cell       Date:  1994-01-28       Impact factor: 41.582

5.  Cellular oxidative responses and mycobacterial growth inhibition in aerosol and intradermal BCG-immunized guinea-pigs.

Authors:  M Lagranderie; C Frehel; C de Chastellier; M Gheorghiu
Journal:  Biologicals       Date:  1991-10       Impact factor: 1.856

Review 6.  Adhesive protein receptors on hematopoietic cells.

Authors:  M E Hemler
Journal:  Immunol Today       Date:  1988-04

7.  BCG-induced protection in guinea pigs vaccinated and challenged via the respiratory route.

Authors:  M Lagranderie; P Ravisse; G Marchal; M Gheorghiu; V Balasubramanian; E H Weigeshaus; D W Smith
Journal:  Tuber Lung Dis       Date:  1993-02

8.  Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

Authors:  G A Colditz; T F Brewer; C S Berkey; M E Wilson; E Burdick; H V Fineberg; F Mosteller
Journal:  JAMA       Date:  1994-03-02       Impact factor: 56.272

9.  Intrapulmonary BCG cell wall vaccination in mice.

Authors:  P D Reuman; E M Ayoub
Journal:  Microbios       Date:  1987

10.  Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection.

Authors:  B E Jones; S M Young; D Antoniskis; P T Davidson; F Kramer; P F Barnes
Journal:  Am Rev Respir Dis       Date:  1993-11
View more
  20 in total

1.  Bacillus Calmette-Guérin vaccination using a microneedle patch.

Authors:  Yasuhiro Hiraishi; Subhadra Nandakumar; Seong-O Choi; Jeong Woo Lee; Yeu-Chun Kim; James E Posey; Suraj B Sable; Mark R Prausnitz
Journal:  Vaccine       Date:  2011-01-28       Impact factor: 3.641

2.  CD4 T cells producing IFN-gamma in the lungs of mice challenged with mycobacteria express a CD27-negative phenotype.

Authors:  I V Lyadova; S Oberdorf; M A Kapina; A S Apt; S L Swain; P C Sayles
Journal:  Clin Exp Immunol       Date:  2004-10       Impact factor: 4.330

3.  Anamnestic responses of mice following Mycobacterium tuberculosis infection.

Authors:  Arati B Kamath; Samuel M Behar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

4.  Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.

Authors:  Leander Grode; Peter Seiler; Sven Baumann; Jürgen Hess; Volker Brinkmann; Ali Nasser Eddine; Peggy Mann; Christian Goosmann; Silke Bandermann; Debbie Smith; Gregory J Bancroft; Jean-Marc Reyrat; Dick van Soolingen; Bärbel Raupach; Stefan H E Kaufmann
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

5.  Resident Th1-like effector memory cells in pulmonary recall responses to Mycobacterium tuberculosis.

Authors:  Jessica Walrath; Lynn Zukowski; Adriana Krywiak; Richard F Silver
Journal:  Am J Respir Cell Mol Biol       Date:  2005-03-18       Impact factor: 6.914

6.  T cell responses to mycobacterial catalase-peroxidase profile a pathogenic antigen in systemic sarcoidosis.

Authors:  Edward S Chen; Jan Wahlström; Zhimin Song; Matthew H Willett; Maria Wikén; Rex C Yung; Erin E West; John F McDyer; Ying Zhang; Anders Eklund; Johan Grunewald; David R Moller
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

7.  Pulmonary Mycobacterium bovis BCG vaccination confers dose-dependent superior protection compared to that of subcutaneous vaccination.

Authors:  Nacho Aguilo; Ana Maria Toledo; Eva Maria Lopez-Roman; Esther Perez-Herran; Eamonn Gormley; Joaquin Rullas-Trincado; Iñigo Angulo-Barturen; Carlos Martin
Journal:  Clin Vaccine Immunol       Date:  2014-02-05

8.  Application of mycobacterial proteomics to vaccine design: improved protection by Mycobacterium bovis BCG prime-Rv3407 DNA boost vaccination against tuberculosis.

Authors:  Hans Joachim Mollenkopf; Leander Grode; Jens Mattow; Maik Stein; Peggy Mann; Bernhard Knapp; Jeffrey Ulmer; Stefan H E Kaufmann
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

9.  Single intranasal mucosal Mycobacterium bovis BCG vaccination confers improved protection compared to subcutaneous vaccination against pulmonary tuberculosis.

Authors:  Lihao Chen; Jun Wang; Anna Zganiacz; Zhou Xing
Journal:  Infect Immun       Date:  2004-01       Impact factor: 3.441

10.  Pathogen-related differences in the abundance of presented antigen are reflected in CD4+ T cell dynamic behavior and effector function in the lung.

Authors:  Parizad Torabi-Parizi; Nienke Vrisekoop; Wolfgang Kastenmuller; Michael Y Gerner; Jackson G Egen; Ronald N Germain
Journal:  J Immunol       Date:  2014-01-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.